SynAct Pharma's CEO is Jeppe Ovlesen, appointed in Mar 2024, has a tenure of 2.33 years. directly owns 0.68% of the company’s shares, worth SEK6.60M. The average tenure of the management team and the board of directors is 2.3 years and 2.3 years respectively.
Key information
Jeppe Ovlesen
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
2.3yrs
CEO ownership
0.7%
Management average tenure
2.3yrs
Board average tenure
2.3yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Jeppe Ovlesen's remuneration changed compared to SynAct Pharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-SEK 112m
Dec 31 2025
n/a
n/a
-SEK 111m
Sep 30 2025
n/a
n/a
-SEK 106m
Jun 30 2025
n/a
n/a
-SEK 91m
Mar 31 2025
n/a
n/a
-SEK 82m
Dec 31 2024
n/a
n/a
-SEK 82m
Sep 30 2024
n/a
n/a
-SEK 155m
Jun 30 2024
n/a
n/a
-SEK 166m
Mar 31 2024
n/a
n/a
-SEK 191m
Dec 31 2023
n/a
n/a
-SEK 216m
Sep 30 2023
n/a
n/a
-SEK 156m
Jun 30 2023
n/a
n/a
-SEK 148m
Mar 31 2023
n/a
n/a
-SEK 129m
Dec 31 2022
SEK 4m
SEK 3m
-SEK 99m
Sep 30 2022
n/a
n/a
-SEK 95m
Jun 30 2022
n/a
n/a
-SEK 89m
Mar 31 2022
n/a
n/a
-SEK 78m
Dec 31 2021
SEK 2m
SEK 2m
-SEK 69m
Sep 30 2021
n/a
n/a
-SEK 52m
Jun 30 2021
n/a
n/a
-SEK 41m
Mar 31 2021
n/a
n/a
-SEK 35m
Dec 31 2020
SEK 2m
SEK 2m
-SEK 27m
Sep 30 2020
n/a
n/a
-SEK 29m
Jun 30 2020
n/a
n/a
-SEK 24m
Mar 31 2020
n/a
n/a
-SEK 23m
Dec 31 2019
SEK 2m
SEK 2m
-SEK 24m
Compensation vs Market: Insufficient data to establish whether Jeppe's total compensation is reasonable compared to companies of similar size in the UK market.
Compensation vs Earnings: Jeppe's compensation has increased whilst the company is unprofitable.
CEO
Jeppe Ovlesen (64 yo)
2.3yrs
Tenure
SEK 3,656,000
Compensation
Mr. Jeppe Ovli Ovlesen, EE, MBA, serves Chief Executive Officer of SynAct Pharma AB since March 20, 2024 and served as its Director since March 20, 2024 until 2025. He serves as Director at Cereno Scientif...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Jeppe Ovlesen
Chief Executive Officer
2.3yrs
SEK 3.66m
0.68% SEK 6.6m
Ann Led
Chief Financial Officer
less than a year
no data
no data
Thomas Boesen
Chief Operating Officer
5.5yrs
no data
0.44% SEK 4.3m
Kristen Harting
Chief Medical Officer
2.4yrs
no data
no data
Mads Bjerregaard
Chief Business Officer
less than a year
no data
0.0054% SEK 52.2k
Malin Wikstrand
Financial Controller
no data
no data
no data
2.3yrs
Average Tenure
Experienced Management: SYNACS's management team is considered experienced (2.3 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Sten Scheibye
Independent Director
2.3yrs
SEK 250.00k
0.24% SEK 2.3m
Vibeke Strand
Member of Clinical Advisory Board
2.5yrs
no data
no data
Mauro Perretti
Member of Scientific Advisory Board
no data
no data
no data
Anders Kronborg
Chairman of Board
2.3yrs
SEK 350.00k
0.14% SEK 1.3m
James Knight
Member of Advisory Board
less than a year
no data
0.14% SEK 1.3m
Sten Sorensen
Director
2.3yrs
SEK 215.00k
0.037% SEK 355.9k
Ravi Rao
Member of Clinical Advisory Board
2.5yrs
no data
no data
Roy Fleischmann
Member of Clinical Advisory Board
2.5yrs
no data
no data
Mauro Teixeira
Member of Scientific Advisory Board
no data
no data
no data
Jeppe Andersen
Independent Director
1.4yrs
SEK 200.00k
0.00089% SEK 8.7k
2.3yrs
Average Tenure
62yo
Average Age
Experienced Board: SYNACS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/30 08:29
End of Day Share Price
2026/07/08 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.